Results 161 to 170 of about 8,510 (199)

Lorlatinib

Reactions Weekly
  +14 more sources

Alectinib/lorlatinib

Reactions Weekly
semanticscholar   +6 more sources

Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China

Frontiers in Oncology
Introduction Lorlatinib, a third-generation ALK inhibitor, has demonstrated strong efficacy in treating advanced ALK-positive NSCLC, though real-world data, particularly from China, are limited.
Guangming Tian, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Di Wu, Xiangjuan Ma, Xiaoling Chen, Sen Han, Jindi Han, Ziran Zhang, J. Long, Xinliang Zhao, J. Fang   +13 more
semanticscholar   +1 more source

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Cancer Discovery
By combining potent targeting of ALK oncoproteins and resistant mutants with brain penetrance and selectivity for ALK over TRK, the ALK inhibitor NVL-655 addresses key limitations of approved ALK inhibitors.
Jessica J. Lin, Joshua C Horan, A. Tangpeerachaikul, A. Swalduz, Augusto Valdivia, Melissa L. Johnson, B. Besse, D. R. Camidge, Toshio Fujino, Satoshi Yoda, Linh Nguyen-Phuong, Hayato Mizuta, L. Bigot, Catline Nobre, Jii Bum Lee, Mi Ra Yu, S. Mente, Yuting Sun, Nancy E Kohl, James R Porter, M. Shair, Viola W Zhu, E. Felip, B. Cho, L. Friboulet, Aaron N. Hata, H. Pelish, A. Drilon   +27 more
semanticscholar   +1 more source

A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib

Case Reports in Oncology
Introduction: We would like to share the case of a 55-year-old male patient with ALK-positive lung cancer with a corpuscular hemolytic anemia following alectinib therapy.
X. Tonnar, Cornelius F. Waller
semanticscholar   +1 more source

Lorlatinib

Reactions Weekly, 2021
  +6 more sources

Lorlatinib

Reactions Weekly, 2023
  +4 more sources

Lorlatinib-induced focal segmental glomerulosclerosis: The first case described in literature

Journal of Onco-Nephrology
A third-generation anaplastic lymphoma kinase (ALK) inhibitor, lorlatinib, plays a crucial role in the management of ALK-rearranged non-small cell lung cancer. The renal effects of the drug are not yet clear.
Micaela Gentile, Valentina Blanco, Marta D'angelo, Chiara Rocca, Livia Bidin, I. Toscani, Elisa Anselmi, Aldo Maffi, R. Scarpioni   +8 more
semanticscholar   +1 more source

Lorlatinib

Reactions Weekly, 2022
  +5 more sources